502850-12-6

Basic information

• Product Name: Aziridine, 2-(4-fluorophenyl)-3-methyl-, (2S,3R)- (9CI)
• Synonyms: Aziridine, 2-(4-fluorophenyl)-3-methyl-, (2S,3R)- (9CI)
• CAS NO: 502850-12-6
• Molecular Formula: C₉H₁₀FN
• Molecular Weight: 151.1808032
• Product Categories: HALIDE
• Mol File: 502850-12-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Aziridine, 2-(4-fluorophenyl)-3-methyl-, (2S,3R)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Aziridine, 2-(4-fluorophenyl)-3-methyl-, (2S,3R)- (9CI)(502850-12-6)
• EPA Substance Registry System: Aziridine, 2-(4-fluorophenyl)-3-methyl-, (2S,3R)- (9CI)(502850-12-6)

Safety Data

• Hazardous Substances Data: 502850-12-6(Hazardous Substances Data)

Upstream product

• 502850-06-8 (1S,2R)-2-amino-1-(4-fluorophenyl)propan-1-ol 
• 1421013-84-4 (1S,2R)-2-(dibenzylamino)-1-(4-fluorophenyl)propan-1-ol 
• 1421117-76-1 (1R,2R)-1-chloro-1-(4-fluorophenyl)propan-2-amine 

Downstream Products

• 1421014-38-1 (2S,3R)-2-(4-fluorophenyl)-3-methyl-1-(4-nitrophenylsulfonyl)aziridine 
• 1421014-47-2 (1R,2R)-15N-(1-(benzylamino)-1-(4-fluorophenyl)propan-2-yl)-4-nitrobenzenesulfonamide 
• 1421014-53-0 (1S,2S)-15N-(2-(benzylamino)-1-(4-fluorophenyl)propan-2-yl)-4-nitrobenzenesulfonamide 
• 1613235-45-2 (1R,2R)-1-azido-1-(4-fluorophenyl)propan-2-amine 

Relevant articles and documents

Synthesis and in vitro characterization of platinum(II) anticancer coordinates using FTIR spectroscopy and NCI COMPARE: A fast method for new compound discovery

Platinum-based drugs have been used for several decades to treat various cancers successfully. Cisplatin is the original compound in this class; it cross-links DNA, resulting in cell cycle arrest and cell death via apoptosis. Cisplatin is effective against several tumor types but exhibits toxic side effects; in addition, tumors often develop resistance. An original in vitro approach is proposed to determine whether platinum-based research compounds are good candidates for further study by comparing them to marketed drugs using FTIR spectroscopy and the COMPARE analysis from the NCI. Both methods can produce fingerprints and highlight differences between the compounds, classifying the candidates and revealing promising derivatives.